Table 1

Association of clinicopathological characteristics with DDIR status in the OAC cohort

	DDIR positive (n=66)		DDIR negative (n=207)		P value
	N	%	N	%	P value
Age (years)
<60	14	21.2	56	27.1	0.035
60–69	20	30.3	92	44.4
≥70	24	36.4	47	22.7
Unknown	8	12.1	12	5.8
Median	66		64		0.049
Range	41–79		28–83
Sex
Male	54	81.8	168	81.2	0.905
Female	12	18.2	39	18.8
Tumour site
Oesophagus	15	22.7	18	8.7	0.009
GOJ, Siewert 1	27	40.9	103	49.8
GOJ, Siewert 2	14	21.2	64	30.9
GOJ, Siewert 3	10	15.2	22	10.6
Clinical T stage
cT1	1	1.5	3	1.4	0.936
cT2	8	12.1	20	9.7
cT3	48	72.7	160	77.3
cT4	2	3	6	2.9
Unknown	7	10.6	18	8.7
Clinical N stage
N0	12	18.2	50	24.2	0.378
N1	39	59.1	121	58.5
N2	6	9.1	10	4.8
N3	3	4.5	5	2.4
Unknown	6	9.1	21	10.1
Pathological T stage
ypT0	6	9.1	6	2.9	0.1
ypT1	11	16.7	20	9.7
ypT2	10	15.2	32	15.5
ypT3	36	54.5	139	67.1
ypT4	3	4.5	10	4.8
Pathological N stage
ypN0	33	50	69	33.3	0.026
ypN1	9	13.6	52	25.1
ypN2	16	24.2	42	20.3
ypN3	8	12.1	44	21.3
Lymph node yield
≥15	45	68.2	151	72.9
<15	21	31.8	55	26.6	0.433
Unknown	0	0	1	0.5
Median	21.5		21		0.863^†
Range	6–41		6–62
Differentiation
Well	4	6.1	3	1.4	0.044
Moderate	16	24.2	74	35.7
Poor	40	60.1	121	58.5
Unknown	6	9.1	9	4.3
Lymphovascular invasion
Negative	25	37.9	61	29.5	0.222
Positive	39	59.1	139	67.1
Unknown	2	3	7	3.4
Circumferential resection margin
Negative	47	71.2	111	53.6	0.007
Positive	15	22.7	85	41.1
Unknown	4	6.1	11	5.3
Neoadjuvant chemotherapy
CFU/CX	12	18.2	33	15.9	0.89
ECF/X	52	78.8	168	81.2
Oxaliplatin/X	1	1.5	4	1.9
Unknown	1	1.5	2	1
Adjuvant chemotherapy received
No	12	18.2	48	23.2	0.448
Yes	26	39.4	75	36.2
Unknown	28	42.4	84	40.6
Pathological response
Responder	11	16.7	14	6.8	0.025
Non-responder	45	68.2	158	76.3
Unknown	10	15.2	35	16.9

Mann-Whitney U test.
CFU, cisplatin and 5-fluorouracil; CX, cisplatin and capecitabine (xeloda); DDIR, DNA damage immune response; ECF/X, epirubicin, cisplatin and 5-fluorouracil/capecitabine (xeloda); GOJ, gastro-oesophageal junction; OAC, oesophageal adenocarcinoma; Oxaliplatin/X, oxaliplatin and capecitabine (xeloda).